<--- Back to Details
First PageDocument Content
Daiichi Sankyo / Biogen Idec / Pharmaceutical drug / ImClone Systems / Pharmaceutical sciences / Technology / Pharmaceutical industry in the United Kingdom / Pharmacology / Pharmaceutical industry / Novo Nordisk
Date: 2012-07-16 15:45:13
Daiichi Sankyo
Biogen Idec
Pharmaceutical drug
ImClone Systems
Pharmaceutical sciences
Technology
Pharmaceutical industry in the United Kingdom
Pharmacology
Pharmaceutical industry
Novo Nordisk

FEATURE  page 51

Add to Reading List

Source URL: www.pharmacytimes.com

Download Document from Source Website

File Size: 59,33 KB

Share Document on Facebook

Similar Documents

Seminars on Drug Discovery & Development Wednesdays 17::00, Lecture Hall 1, Pharmazentrum, Klingelbergstrasse 50, Basel Feb 24, 16 Prof. Dr. G. Klebe, Institute of Pharmaceutical Chemistry, Philipps-University Mar

DocID: 1vnYL - View Document

Send Orders of Reprints at 614 Current Pharmaceutical Design, 2013, 19, Rejuvenating Sirtuins: The Rise of a New Family of Cancer Drug Targets

DocID: 1v1vA - View Document

eclipse | RBM data sheet Risk Based Monitoring (RBM) Drug costs are soaring. The pharmaceutical, biotech and CRO industries are more competitive than ever before. Companies like yours are looking for ways to reduce expe

DocID: 1uZyk - View Document

2nd APV Conference on “Highly Potent Drug Products in the Pharmaceutical Industry” 26 to 27 September 2018 Mannheim, Germany

DocID: 1utU5 - View Document

AIDS Treatment Activists Coalition (ATAC) Pharmaceutical Company HIV/AIDS Report Card Issued by the ATAC Drug Development Committee September 10, 2009

DocID: 1u8Vg - View Document